A simple scoring system version of the SLE Risk Probability Index*
| Feature | Score |
| Malar rash or maculopapular rash† | 3 |
| Subacute cutaneous lupus erythematosus or discoid lupus erythematosus† | 2 |
| Alopecia‡ | 1.5 |
| Mucosal ulcers§ | 1 |
| Arthritis§ | 2 |
| Serositis§ | 1.5 |
| Leucopenia<4000/μL (at least once)† | 1.5 |
| Thrombocytopenia or autoimmune haemolytic anaemia† | 4.5 |
| Neurological disorder‡ | 1.5 |
| Proteinuria>500 mg/24 hours† | 4.5 |
| ANA† | 3 |
| Low C3 and C4† | 2 |
| Immunological disorder (any of: anti-DNA, anti-Sm, anti-phospholipid antibodies)¶ | 2.5 |
| Interstitial lung disease** | –1 |
| SLE if total score >7†† |
*Apply the model in individuals with clinical suspicion for SLE. Each feature is counted if present (ever) and if not explained by other cause (eg, drug effects, infections, malignant disorders, alternative more likely disease).
†Defined as in Aringer et al.9 10
‡Defined as in Petri et al.8
§Defined as in Hochberg.27
¶Defined as in Hochberg27 modified to include also positive anti-β2 glycoprotein IgG or IgM or IgA antibodies.
**Radiologic features of lung disease suggesting inflammation and fibrosis of the alveoli, distal airways and septal interstitium of the lung, as observed with a high-resolution CT scan of the chest.
††When operated at a threshold (sum of individual scores) of >7 (out of a maximum value 30.5), the sensitivity, specificity and accuracy rates are 94.2%, 94.4% and 94.2%, respectively.
ANA, antinuclear antibodies; SLE, systemic lupus erythematosus.